Children's cough syrup recalled nationwide over bacterial risk that ‘can cause death'
The voluntary recall affects five lots of the syrup, sold in 4-fluid-ounce amber bottles and distributed in stores — including Walgreens, Target, CVS, and Safeway — and online between December 14, 2022, and June 4, 2025.
The affected product bears the UPC 7-56184-10737-9 and includes lot numbers 0039 (exp. 11/2025), 0545 (01/2026), 0640 (02/2026), 0450 (05/2026), and 1198 (12/2026). The recall extends to all lots still within their expiration dates.
The bacteria found in the cough syrup, Bacillus cereus, can cause two distinct types of gastrointestinal illness. One type leads to nausea, vomiting and stomach cramps within hours of ingestion. The other manifests later, often with diarrhea and abdominal discomfort.
'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death,' the FDA warned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
US FDA approves Ionis' drug for rare genetic disorder
By Sneha S K and Bageshri Banerjee (Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder. Shares of the company were up 1.1% in afternoon trading. The drug, Dawnzera, is approved as a so-called "prophylaxis" to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. The condition causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face. Dawnzera will be available in the United States in the coming days with a list price of $57,462 per dose, the company said. HAE is estimated to affect about 7,000 patients in the U.S., according to Ionis. The drug, chemically known as donidalorsen, prevents HAE attacks by lowering levels of a protein called prekallikrein (PKK) that drives swelling and inflammation. Dawnzera can be self-administered through an under-the-skin injection once every four or eight weeks. The approval was supported by late-stage study results that showed the drug, dosed once every four weeks, reduced monthly attacks by 81% compared to a placebo over 24 weeks. Current FDA-approved therapies for HAE fall into two groups: prophylaxis to prevent attacks and on-demand medicines to treat acute attacks. Other approved prophylactic drugs include Takhzyro, developed by Japan's Takeda Pharmaceutical and Haegarda from CSL Behring. There is a lot of excitement for donidalorsen as patients who are not doing well on existing therapies have an option to switch to Dawnzera, which has a higher efficacy, TD Cowen analyst Yaron Werber said ahead of the approval. Takhzyro, given every two weeks, showed an average of 87% fewer attacks compared to a placebo over 6.5 months in a separate study involving adult and adolescent patients. Werber estimates peak annual sales of Ionis' drug to be $509 million by 2032. Solve the daily Crossword
Newsweek
8 hours ago
- Newsweek
7Up Recalled Issued After Sugar Mix Up in Thousands of Cans
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A voluntary recall has been issued for nearly 2,000 cases of 7Up Zero Sugar Tropical Soda sold in Alabama, Florida and Georgia after it was discovered that some cans labeled "Zero Sugar" actually contain sugar. The recall, initiated on July 31, 2025, by Buffalo Rock Company Inc., is classified as Class II by the U.S. Food and Drug Administration (FDA), meaning exposure to the mislabeled product may cause temporary or medically reversible health consequences but is unlikely to lead to serious adverse health effects. Newsweek reached out to Buffalo Rock for comment via an online form on the company's website. Newsweek also contacted Keurig Dr Pepper, the manufacturer of 7Up, for comment via email. Why It Matters Consumers with dietary restrictions related to sugar intake, such as those managing diabetes, may unknowingly ingest sugar if they consume the mislabeled soda. The health implications can be serious for those relying on accurate nutritional labeling to maintain blood glucose levels or manage metabolic conditions. Newsweek What To Know The product in question is sold in 12-pack cartons labeled "7up Tropical Flavored Soda." The aluminum cans themselves are marked "7UP Zero Sugar Tropical Soda" with a UPC code of 078000037975, while the carton bears UPC code 078000037982. The affected lot numbers are XXXXBR062156 and XXXXBR062256, with a use-by date of MAR 23 26. Buffalo Rock, a beverage bottling and distribution company based in Birmingham, Alabama, did not issue a public press release for the recall but notified distributors through multiple methods, including email, fax, phone, letters, and direct visits. FDA inspectors carry out a hazard assessment before issuing one of three risk levels. The three classifications are these: Class I —a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. —a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Class II —a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. —a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class III—a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. What People Are Saying The FDA said on its website: "Product problems should be reported to the FDA when there is a concern about the quality, authenticity, performance, or safety of any medication or device. Problems with product quality may occur during manufacturing, shipping, or storage. They include ... labeling concerns."
Business Insider
16 hours ago
- Business Insider
Why Is EnVVeno Medical Stock (NVNO) Down 70% Today?
EnVVeno Medical (NVNO) stock took a beating after the medical device company's VenoValve surgical replacement venous valve for severe deep chronic venous insufficiency was rejected by the U.S. Food and Drug Administration (FDA). The FDA sent a non-approvable letter to EnVVeno Medical, stating it couldn't approve the Premarket Approval application for the product in its current form. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to EnVVeno Medical, the FDA wouldn't approve the medical device because 'the favorable revised Venous Clinical Severity Score (rVCSS) data generated by the study to show clinical improvement, together with the improvements in pain scores and venous specific quality of life indicators was not sufficient on its own to determine favorability of the benefit risk profile for the VenoValve.' EnVVeno Medical noted its disappointment with the FDA's decision and is weighing options, including a potential resubmission or appeal. The company also said that it will take into account what it has learned from this letter in its development of enVVe a non-surgical replacement venous valve that it plans to submit an IDE application for. EnVVeno Medical Stock Movement Today EnVVeno Medical stock was down 71.84% in pre-market trading, following a 16.12% drop yesterday. The shares were still up 38.74% year-to-date but were down 20.94% over the past 12 months. Today's news came with heavy trading, as some 3.6 million shares changed hands, compared to a three-month daily average of about 148,000 units. Is EnVVeno Medical Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of EnVVeno Medical is thin. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates NVNO stock a Neutral (58) with no price target. It cites 'robust technical performance, which is somewhat overshadowed by challenging financial metrics' as reasons for this stance.
